CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free ...
GlobalData on MSN6h
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...
Finanznachrichten8h
Lindis Biotech GmbH: LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab
Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting and if approved catumaxomab will be the only approved drug for ...
Le Lézard9h
LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab
Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting and if approved catumaxomab will be the only approved drug for ...
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...
Armed robbery in Revesby10h
Pharmanovia, Lindis Ink Deal on Catumaxomab for Ascites
Catumaxomab Received a Positive Opinion From the EMA's Committee for Medicinal Products for Human Use (CHMP) at Its October 2024 Meeting and If ...
Pharmabiz10h
European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on the results from the LAURA phase III trial, which were published in The ...
Daily1h
AstraZeneca Tagrisso recommended for approval in EU by CHMP for patients with unresectable EGFR mutated lung cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion ...
Mena FN15h
Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech To Commercialise Catumaxomab For Treatment O...
Catumaxomab received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting with EU marketing authorization ...
EuropaWire8h
AstraZeneca’s Tagrisso Receives EU Recommendation as First Targeted Therapy for Unresectable EGFR-Mutated Lung Cancer
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...
Le Lézard16h
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Vir Biotechnology, Inc. today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebsiran, in people with chronic hepatitis delta ...
STAT9h
In first meeting of FDA’s digital health advisory committee, generative AI is up for debate
The FDA's digital health advisory committee is expected to weigh in on how generative AI should be regulated by the agency.